Assessment of Public Opinion on Transparency at the US Food and Drug Administration

被引：3
|
作者：
Azad, Tej D. [1 ]
Plott, Caroline F. [2 ]
Gielen, Andrea C. [3 ]
Sharfstein, Joshua M. [4 ]
机构：
[1] Johns Hopkins Univ Hosp, Dept Neurosurg, Baltimore, MD 21287 USA
[2] Johns Hopkins Sch Med, Baltimore, MD USA
[3] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Behav & Soc, Baltimore, MD USA
[4] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, 615 N Wolfe St,W1033F, Baltimore, MD 21205 USA
来源：
JAMA NETWORK OPEN | 2022年 / 5卷 / 02期
关键词：
D O I：
10.1001/jamanetworkopen.2022.0026
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页数：6
相关论文
共 50 条
  • [1] Transparency at the US Food and Drug Administration
    Califf, Robert M.
    JOURNAL OF LAW MEDICINE & ETHICS, 2017, 45 : 24 - 28
  • [2] Increasing Transparency at the US Food and Drug Administration
    Steinbrook, Robert
    JAMA INTERNAL MEDICINE, 2019, 179 (08) : 1146 - 1147
  • [3] Blueprint for Transparency at the US Food and Drug Administration
    McClellan, Courtney
    JOURNAL OF LAW MEDICINE & ETHICS, 2017, 45 : 1 - 1
  • [4] Blueprint for Transparency at the US Food and Drug Administration INTRODUCTION
    Davis, Anna L.
    Miller, James Dabney
    Sharfstein, Joshua M.
    Kesselheim, Aaron S.
    JOURNAL OF LAW MEDICINE & ETHICS, 2017, 45 : 5 - 6
  • [5] Another Reason for Greater Transparency at the US Food and Drug Administration
    Steinbrook, Robert
    JAMA INTERNAL MEDICINE, 2021, 181 (04) : 529 - 529
  • [6] Transparency and Dermatologic Device Approval by the US Food and Drug Administration
    Ezaldein, Harib H.
    Scott, Jeffrey F.
    Yin, Emily S.
    Ventura, Alessandra
    DeRuyter, Nicholaas P.
    Leffell, David J.
    JAMA DERMATOLOGY, 2018, 154 (03) : 273 - 280
  • [7] Transparency at the Food and Drug Administration.
    Asamoah, Afia K.
    Sharfstein, Joshua M.
    NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (25): : 2341 - 2343
  • [8] Product Approval and Public Health at the US Food and Drug Administration
    Lurie, Peter
    Sharfstein, Joshua M.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2021, 326 (24): : 2469 - 2470
  • [9] Public opinion regarding US Food and Drug Administration approval of aducanumab and potential policy responses: A nationally representative survey
    DiStefano, Michael J.
    Alexander, G. Caleb
    Polsky, Daniel
    Anderson, Gerard F.
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2022, 70 (06) : 1685 - 1694
  • [10] Health risk assessment practices in the US Food and Drug Administration
    Gaylor, DW
    Axelrad, JA
    Brown, RP
    Cavagnaro, JA
    Cyr, WH
    Hulebak, KL
    Lorentzen, RJ
    Miller, MA
    Mulligan, LT
    Schwetz, BA
    REGULATORY TOXICOLOGY AND PHARMACOLOGY, 1997, 26 (03) : 307 - 321
12345